Home |
About Us |
Investor Relations |
Products & Services |
Science & Technology |
People |
News & Events |
Contact Us
News |
Events
|
|
 |
|
||
 |
||
| |
|
 |
 |
|
12 August 2003 Holding(s) in Company Pursuant to Schedule 5 of the AIM Rules, regarding the notification of major interests in shares, Cyprotex announces that on 11 August 2003 Nordan Holdings Limited (“Nordan”), an investment vehicle controlled by Aubach Capital Partners Limited (“Aubach”), acquired 29.9% of the Company’s Ordinary Share Capital, which was previously held by Mr Paul Davidson. Whilst Paul Davidson has a partial economic interest in Nordan, Nordan is controlled by Aubach, a private investment vehicle in which Paul Davidson has no legal or beneficial interest. The stock, comprising approximately 27.1 million Ordinary Shares, was acquired at a price of 10 pence per share. By virtue of an agreement falling under section 204 of the Companies Act between Nordan, Aubach and Mr Paul Davidson, each of these parties has a notifiable interest in 29.9% of Cyprotex plc’s share capital. Mr Davidson has no further notifiable interest in Cyprotex’s share capital. For further information: Mr John Nicholson, Chief Operating Officer Cyprotex PLC Tel: +44 (0) 1625 505 100 j.nicholson@cyprotex.com www.cyprotex.com Media enquiries: Henry Harrison-Topham Bankside Consultants Limited Tel: +44 (0) 20 7444 4140 henry.ht@bankside.com www.bankside.com |
|
|
 |
|
